P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications

Mariagrazia Michieli, Daniela Damiani, Anna Ermacora, Paola Masolini, Donatella Raspadori, Giuseppe Visani, R. J. Scheper, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance associated protein (MRP) expression and the blast cells' intracellular daunorubicin accumulation (IDA) were evaluated in 96 previously untreated cases of de novo acute non-lymphocytic leukaemia (ANLL). 47/96 patients (49%) were classified as PGP+ 44/96 (46%) as LRP+, and 8/96 (8%) as MRP+. The more frequent MDR clusters were PGP-/LRP-/MRP- (32/96 cases, 33%) and the PGP+/LRP+/MRP- (27/96 cases, 28%) followed by PGP+/LRP- /MRP- (15/96 cases, 16%) and PGP-/LRP+/MRP- (14/96 cases, 14%). A favourable karyotype was observed more frequently in PGP- and LRP- cases. A highly significant correlation was found between either PGP or LRP overexpression and leukaemic blast cell IDA. All the patients received standard induction and consolidation treatments containing MDR-related (idarubicin, mitoxantrone, etoposide) and other (arabinosyl cytosine) drugs. Multivariate analysis showed that PGP overexpression was significantly associated with a poor response to treatment, both in terms of primary resistance or shorter survival. Other independent prognostic factors were age and cytogenetics. LRP overexpression did not reach statistical significance, although for LRP+ cases the trend was unfavourable. Due to small numbers, no conclusion could be made regarding MRP overexpression, but 5/8 cases showed unfavourable karyotypic abnormalities, 8/8 had a defective IDA and 6/8 failed to achieve remission. This study showed that both PGP and LRP overexpression are common features in de novo ANLL at onset whereas MRP overexpression is more rare. It suggested that overexpression of one of the MDR related proteins was associated with a defective IDA, and confirmed that, in addition to age and cytogenetics, PGP retains an independent prognostic value. It also suggested that LRP did not affect clinical outcome when patients were treated with idarubicin or mitoxantrone and arabinosyl cytosine.

Original languageEnglish
Pages (from-to)328-335
Number of pages8
JournalBritish Journal of Haematology
Volume104
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Multidrug Resistance-Associated Proteins
P-Glycoprotein
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Daunorubicin
Idarubicin
Mitoxantrone
Cytosine
Cytogenetics
major vault protein
Etoposide
Karyotype

Keywords

  • Acute leukaemia
  • Lung resistance-related protein
  • Multidrug resistance associated protein
  • P-glycoprotein

ASJC Scopus subject areas

  • Hematology

Cite this

P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias : Biological and clinical implications. / Michieli, Mariagrazia; Damiani, Daniela; Ermacora, Anna; Masolini, Paola; Raspadori, Donatella; Visani, Giuseppe; Scheper, R. J.; Baccarani, Michele.

In: British Journal of Haematology, Vol. 104, No. 2, 1999, p. 328-335.

Research output: Contribution to journalArticle

Michieli, Mariagrazia ; Damiani, Daniela ; Ermacora, Anna ; Masolini, Paola ; Raspadori, Donatella ; Visani, Giuseppe ; Scheper, R. J. ; Baccarani, Michele. / P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias : Biological and clinical implications. In: British Journal of Haematology. 1999 ; Vol. 104, No. 2. pp. 328-335.
@article{e4f3f520652b4812a8cb92df2f42e601,
title = "P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications",
abstract = "P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance associated protein (MRP) expression and the blast cells' intracellular daunorubicin accumulation (IDA) were evaluated in 96 previously untreated cases of de novo acute non-lymphocytic leukaemia (ANLL). 47/96 patients (49{\%}) were classified as PGP+ 44/96 (46{\%}) as LRP+, and 8/96 (8{\%}) as MRP+. The more frequent MDR clusters were PGP-/LRP-/MRP- (32/96 cases, 33{\%}) and the PGP+/LRP+/MRP- (27/96 cases, 28{\%}) followed by PGP+/LRP- /MRP- (15/96 cases, 16{\%}) and PGP-/LRP+/MRP- (14/96 cases, 14{\%}). A favourable karyotype was observed more frequently in PGP- and LRP- cases. A highly significant correlation was found between either PGP or LRP overexpression and leukaemic blast cell IDA. All the patients received standard induction and consolidation treatments containing MDR-related (idarubicin, mitoxantrone, etoposide) and other (arabinosyl cytosine) drugs. Multivariate analysis showed that PGP overexpression was significantly associated with a poor response to treatment, both in terms of primary resistance or shorter survival. Other independent prognostic factors were age and cytogenetics. LRP overexpression did not reach statistical significance, although for LRP+ cases the trend was unfavourable. Due to small numbers, no conclusion could be made regarding MRP overexpression, but 5/8 cases showed unfavourable karyotypic abnormalities, 8/8 had a defective IDA and 6/8 failed to achieve remission. This study showed that both PGP and LRP overexpression are common features in de novo ANLL at onset whereas MRP overexpression is more rare. It suggested that overexpression of one of the MDR related proteins was associated with a defective IDA, and confirmed that, in addition to age and cytogenetics, PGP retains an independent prognostic value. It also suggested that LRP did not affect clinical outcome when patients were treated with idarubicin or mitoxantrone and arabinosyl cytosine.",
keywords = "Acute leukaemia, Lung resistance-related protein, Multidrug resistance associated protein, P-glycoprotein",
author = "Mariagrazia Michieli and Daniela Damiani and Anna Ermacora and Paola Masolini and Donatella Raspadori and Giuseppe Visani and Scheper, {R. J.} and Michele Baccarani",
year = "1999",
doi = "10.1046/j.1365-2141.1999.01172.x",
language = "English",
volume = "104",
pages = "328--335",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias

T2 - Biological and clinical implications

AU - Michieli, Mariagrazia

AU - Damiani, Daniela

AU - Ermacora, Anna

AU - Masolini, Paola

AU - Raspadori, Donatella

AU - Visani, Giuseppe

AU - Scheper, R. J.

AU - Baccarani, Michele

PY - 1999

Y1 - 1999

N2 - P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance associated protein (MRP) expression and the blast cells' intracellular daunorubicin accumulation (IDA) were evaluated in 96 previously untreated cases of de novo acute non-lymphocytic leukaemia (ANLL). 47/96 patients (49%) were classified as PGP+ 44/96 (46%) as LRP+, and 8/96 (8%) as MRP+. The more frequent MDR clusters were PGP-/LRP-/MRP- (32/96 cases, 33%) and the PGP+/LRP+/MRP- (27/96 cases, 28%) followed by PGP+/LRP- /MRP- (15/96 cases, 16%) and PGP-/LRP+/MRP- (14/96 cases, 14%). A favourable karyotype was observed more frequently in PGP- and LRP- cases. A highly significant correlation was found between either PGP or LRP overexpression and leukaemic blast cell IDA. All the patients received standard induction and consolidation treatments containing MDR-related (idarubicin, mitoxantrone, etoposide) and other (arabinosyl cytosine) drugs. Multivariate analysis showed that PGP overexpression was significantly associated with a poor response to treatment, both in terms of primary resistance or shorter survival. Other independent prognostic factors were age and cytogenetics. LRP overexpression did not reach statistical significance, although for LRP+ cases the trend was unfavourable. Due to small numbers, no conclusion could be made regarding MRP overexpression, but 5/8 cases showed unfavourable karyotypic abnormalities, 8/8 had a defective IDA and 6/8 failed to achieve remission. This study showed that both PGP and LRP overexpression are common features in de novo ANLL at onset whereas MRP overexpression is more rare. It suggested that overexpression of one of the MDR related proteins was associated with a defective IDA, and confirmed that, in addition to age and cytogenetics, PGP retains an independent prognostic value. It also suggested that LRP did not affect clinical outcome when patients were treated with idarubicin or mitoxantrone and arabinosyl cytosine.

AB - P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance associated protein (MRP) expression and the blast cells' intracellular daunorubicin accumulation (IDA) were evaluated in 96 previously untreated cases of de novo acute non-lymphocytic leukaemia (ANLL). 47/96 patients (49%) were classified as PGP+ 44/96 (46%) as LRP+, and 8/96 (8%) as MRP+. The more frequent MDR clusters were PGP-/LRP-/MRP- (32/96 cases, 33%) and the PGP+/LRP+/MRP- (27/96 cases, 28%) followed by PGP+/LRP- /MRP- (15/96 cases, 16%) and PGP-/LRP+/MRP- (14/96 cases, 14%). A favourable karyotype was observed more frequently in PGP- and LRP- cases. A highly significant correlation was found between either PGP or LRP overexpression and leukaemic blast cell IDA. All the patients received standard induction and consolidation treatments containing MDR-related (idarubicin, mitoxantrone, etoposide) and other (arabinosyl cytosine) drugs. Multivariate analysis showed that PGP overexpression was significantly associated with a poor response to treatment, both in terms of primary resistance or shorter survival. Other independent prognostic factors were age and cytogenetics. LRP overexpression did not reach statistical significance, although for LRP+ cases the trend was unfavourable. Due to small numbers, no conclusion could be made regarding MRP overexpression, but 5/8 cases showed unfavourable karyotypic abnormalities, 8/8 had a defective IDA and 6/8 failed to achieve remission. This study showed that both PGP and LRP overexpression are common features in de novo ANLL at onset whereas MRP overexpression is more rare. It suggested that overexpression of one of the MDR related proteins was associated with a defective IDA, and confirmed that, in addition to age and cytogenetics, PGP retains an independent prognostic value. It also suggested that LRP did not affect clinical outcome when patients were treated with idarubicin or mitoxantrone and arabinosyl cytosine.

KW - Acute leukaemia

KW - Lung resistance-related protein

KW - Multidrug resistance associated protein

KW - P-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=0032911283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032911283&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1999.01172.x

DO - 10.1046/j.1365-2141.1999.01172.x

M3 - Article

C2 - 10050716

AN - SCOPUS:0032911283

VL - 104

SP - 328

EP - 335

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -